AstraZeneca agrees to pay up to £4.7bn for cancer drug
by Jasper Jolly and agencies from Science | The Guardian on (#566QG)
UK-based company hopes deal with Daiichi Sankyo will lead to new breast and lung cancer treatment
AstraZeneca has agreed a deal worth as much as 4.7bn with a Japanese drug company to develop and market a potential new cancer treatment.
The British-Swedish pharmaceutical company said it would pay $1bn (800m) upfront to its partner, Daiichi Sankyo, in what is the latest of a series of bets by the pharma company on oncology treatments.
Continue reading...